Vyleesi Regret, Stopping, and Restarting: What Real Users Experience

Why So Many Women Feel Regret After the First Injection

Regret hits fast with Vyleesi. A substantial share of users report that the first or second injection was nothing like they expected, and the gap between the marketing promise and the lived experience is the most common reason women walk away.

The FDA label lists nausea in approximately 40% of participants in the RECONNECT phase 3 program, with 13% describing it as severe. [1] That figure comes from pooled data across two randomized trials (RECONNECT-1 and RECONNECT-2, combined N=1,267). Flushing occurred in roughly 20% of users. These numbers do not soften when you see them live at 11 p.m. On a Friday night with a date waiting.

The Expectation Gap

Vyleesi is not a fast, invisible pill. It is a subcutaneous injection that must be given 45 minutes before anticipated sexual activity, and the nausea can arrive before desire does. Women who expected a libido "switch" often describe the first experience as physically miserable rather than sensual, a description that tracks closely with user-review patterns on Drugs.com and Trustpilot.

That expectation gap is not irrational. Direct-to-consumer advertising for HSDD treatments emphasizes desire improvement, not the procedural reality of self-injection alongside a 40% nausea probability.

What the Trials Actually Showed

In the RECONNECT trials, the co-primary endpoints were the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. [2] Bremelanotide produced a statistically significant improvement on both scales versus placebo (P<0.001), but the absolute between-group difference was modest: roughly 0.5 points on the FSFI desire domain (scale 1.2 to 6.0). A statistically significant finding is not the same as a significant personal experience for every user, and that distinction drives a meaningful share of regret.

The Most Common Reasons Women Stop Vyleesi

Nausea and Vomiting

Nausea is the single largest driver of discontinuation. In the RECONNECT pooled safety data, nausea led to study discontinuation in roughly 8% of participants, making it the top adverse-event dropout cause. [1] Home use without antiemetic pre-treatment tends to be worse than the controlled trial setting, where participants were coached extensively on timing and hydration.

Eating a low-fat meal before injection reduces peak bremelanotide plasma concentration. The FDA-approved prescribing information specifically notes that a high-fat meal increases AUC by approximately 37%, which likely amplifies nausea. [1] Many women who "quit" Vyleesi were simply not given this practical instruction at the time of prescribing.

Flushing and the "Hot Flash" Problem

About one in five users experiences flushing, which can feel like a sudden, intense hot flash lasting 15 to 20 minutes. For women already dealing with perimenopausal vasomotor symptoms, this side effect can be misread as a worsening of their existing condition. Peri- and postmenopausal women should note that Vyleesi is approved only for premenopausal HSDD, a distinction addressed more fully by the Endocrine Society's clinical practice guideline on female sexual dysfunction. [3]

Injection Site Pain and Anxiety

Self-injection anxiety is underreported in trial data because participants are trained and supervised. In real-world use, injection hesitation or poor technique can cause bruising, pain, or subtherapeutic delivery. Women with needle anxiety may abandon the therapy after one or two attempts before the drug ever has a fair pharmacological trial.

"It Didn't Do Anything"

A subset of users experience no discernible effect, no nausea, no flushing, and no increase in desire. Bremelanotide works through MC3R and MC4R melanocortin receptor agonism in the central nervous system. [4] Receptor expression variability and the multifactorial nature of HSDD mean that some women may simply be non-responders. The RECONNECT responder analysis identified approximately 25% of treated women as "meaningful responders," meaning a substantial majority did not meet that threshold. [2]

Is It Safe to Stop Vyleesi Abruptly?

Yes. Bremelanotide has no known physiological dependence mechanism. The drug is cleared renally with a terminal half-life of approximately 2.7 hours. [1] There is no receptor downregulation requiring a taper, no hormonal axis suppression to reverse, and no rebound HSDD that is worse than baseline. You can stop after one injection or after fifty without any medically supervised withdrawal protocol.

The only clinical caution at discontinuation is in women using Vyleesi off-schedule for underlying cardiovascular risk: bremelanotide transiently increases blood pressure by approximately 2 to 4 mmHg (mean) and decreases heart rate by approximately 4 to 5 bpm for roughly 12 hours post-injection. [1] Both values return to baseline. Stopping eliminates that transient hemodynamic effect, which is a benefit, not a risk, for cardiovascular patients.

Reconsidering the Restart: Who Should Try Again

Stopping does not mean Vyleesi failed you permanently. The decision to restart should be guided by an honest answer to one question: was the reason you stopped a manageable side effect, or a fundamental lack of efficacy?

The Restart Decision Framework

Use this three-branch logic before restarting:

Branch 1: You stopped because of nausea. A restart with antiemetic pre-treatment is clinically supported. Ondansetron 8 mg oral taken 1 hour before injection significantly reduces nausea in clinical practice (though no head-to-head Vyleesi-plus-ondansetron RCT exists, the pharmacological rationale is sound, and prescribers regularly use this approach). Separately, ensuring a low-fat, moderate-carbohydrate meal 2 to 3 hours before injection and avoiding alcohol that day are the two most consistently helpful behavioral modifications reported by women who successfully restarted.

Branch 2: You stopped because it did not work. If you used Vyleesi fewer than three times at correctly timed intervals, you have not given the drug a fair trial. The RECONNECT protocol required a 4-week minimum-use period before efficacy assessment. A single injection is not an adequate sample. Restart with a structured 8-injection trial over 4 to 8 weeks before concluding non-response.

Branch 3: You stopped because of persistent cardiovascular symptoms, severe uncontrollable hypertension, or hypersensitivity. Do not restart. The FDA prescribing information lists uncontrolled hypertension and cardiovascular disease as contraindications. [1] These are hard stops, and alternative HSDD therapies (including flibanserin for premenopausal women or, off-label, low-dose testosterone as evaluated in APHRODITE [5]) should be discussed with your prescriber.

Restarting After a Long Break

There is no pharmacological argument against restarting Vyleesi months or years after stopping. The drug does not create tolerance, and receptor sensitivity does not appear to change with prior exposure. Women who restart after a 6-month or longer break essentially start fresh from a pharmacodynamic standpoint.

The practical issue is prescription renewal. Bremelanotide is a Schedule V controlled substance in some state formularies and requires a current HSDD diagnosis. A telehealth reassessment visit is generally sufficient to renew the prescription if your diagnosis and premenopausal status are unchanged.

What Reddit and User Review Platforms Actually Reveal

Community forums carry real clinical signal when read carefully. Across Drugs.com reviews, Trustpilot, and Reddit threads (primarily r/DeadBedrooms, r/Vyleesi, and r/WomensHealth), several patterns emerge consistently.

The Dominant Reddit Narrative

The most upvoted Vyleesi threads on Reddit are dominated by two experiences: severe nausea on the first injection, and cautious optimism from women who pushed through to the third or fourth use. A recurring comment pattern describes the nausea as "worth it" once users discovered ondansetron pre-treatment, low-fat eating, and lying down for 30 minutes post-injection.

Women who report positive outcomes on Reddit almost always mention that their prescriber gave them detailed instructions; women who report negative outcomes almost always mention that their prescriber said "inject 45 minutes before" and nothing else. The information quality at the point of prescribing appears to be a stronger predictor of user experience than the pharmacology alone.

Drugs.com and Trustpilot Sentiment

On Drugs.com, Vyleesi carries a mean rating of approximately 5.2 out of 10 as of mid-2025, with the effectiveness subscale slightly higher than the ease-of-use subscale. The most common positive reviews describe a "noticeable mental shift" toward desire within 30 to 45 minutes; the most common negative reviews describe nausea so severe that the user's partner spent the night taking care of them rather than the intended activity.

Trustpilot data skews negative for Vyleesi because unhappy customers are more likely to leave unsolicited reviews. This is a general property of voluntary review platforms and does not reflect the controlled-trial responder rate.

Managing the Side Effects That Drive Most Quits

Nausea Protocol

1. Eat a low-fat meal (under 10 g fat) 2 to 3 hours before injection.
2. Take ondansetron 8 mg oral or dissolving tablet 60 minutes before injection if your prescriber approves it.
3. Stay well hydrated throughout the day of use.
4. Lie flat or reclined for 30 to 60 minutes after injection.
5. Avoid alcohol for at least 12 hours before use.

The FDA label confirms that avoiding high-fat food reduces the rate of peak bremelanotide absorption and correlates with lower nausea rates. [1] No clinical trial has tested this exact protocol in sequence, but each step has independent pharmacological support.

Flushing Management

Flushing is largely benign and self-limiting at 15 to 20 minutes. Staying in a cool room, using a fan, and avoiding hot beverages immediately post-injection reduces subjective severity. Patients with rosacea or severe menopausal hot flashes should discuss this side effect specifically before starting or restarting.

Injection Technique

Bremelanotide must be injected subcutaneously into the abdomen or thigh. Common technique errors include injecting into muscle (intramuscularly rather than subcutaneously), using a site that is currently bruised, and injecting too close to the navel. The autoinjector is pre-filled and single-use. Reviewing the manufacturer's injection guide before each restart attempt reduces procedural errors.

Vyleesi vs. Flibanserin: Choosing the Right HSDD Tool

Some women switch from Vyleesi to flibanserin (Addyi) after a difficult experience. Both are FDA-approved for premenopausal HSDD, and both have modest effect sizes in trials.

Flibanserin (100 mg oral, taken nightly) produced a statistically significant but modest improvement in satisfying sexual events (SSEs) in the BEGONIA and ORCHID trials, with a net increase of approximately 0.5 additional SSEs per month versus placebo. [6] Its main drawbacks are CNS depression, hypotension (especially with alcohol, a black-box warning), and the need for daily dosing rather than on-demand use.

Bremelanotide's on-demand mechanism is its main clinical advantage: no daily pill, no alcohol restriction except around the time of use, and no CNS depression. For women who can tolerate the injection and the transient nausea, the on-demand model often fits better into real-world sexual spontaneity (or semi-planned intimacy) than a nightly pill.

The American College of Obstetricians and Gynecologists (ACOG) notes that both agents are options for HSDD but emphasizes that shared decision-making, including discussion of side effect profiles and patient preference, should guide selection. [7]

Cardiovascular Cautions Worth Reviewing Before Restart

Bremelanotide's transient blood pressure effect is not trivial for every patient. In the RECONNECT safety data, mean systolic blood pressure increased by approximately 2 mmHg and mean diastolic by approximately 1 to 2 mmHg within 12 hours of a dose, returning to baseline after 12 hours. [1]

For women with controlled hypertension (on antihypertensive therapy), the risk is likely low if blood pressure is well managed. For women with uncontrolled hypertension (systolic above 140 mmHg despite treatment), the FDA label contraindicates use. [1] This means a blood pressure check before restarting is a reasonable clinical step, particularly if your cardiovascular status has changed since you last used the drug.

What a Prescriber Should Tell You Before You Start (or Restart)

The gap between trial outcomes and real-world outcomes with Vyleesi traces significantly to inadequate pre-prescribing counseling. A 2021 commentary in the Journal of Sexual Medicine noted that HSDD pharmacotherapy outcomes correlate with patient education on realistic expectations, side-effect anticipation, and behavioral modifications. [8]

Before starting or restarting bremelanotide, a prescriber should cover:

• The 40% nausea probability and how to reduce it.
• The on-demand, not daily, dosing structure and the 24-hour spacing requirement.
• The blood pressure increase and cardiovascular contraindications.
• The modest responder rate (approximately 25%) and what "response" actually looks like in practice.
• The option to pre-treat with ondansetron and the foods to avoid on injection days.

If your prior prescriber did not cover these points, that omission, not the drug itself, may have been the reason your first trial failed.

Does Vyleesi Work for Everyone?

No. Roughly 25% of women in the RECONNECT trials met the threshold for meaningful response on desire-domain scoring. [2] That figure means the majority of users will not achieve what most people would describe as a clear, noticeable improvement. Non-response is more likely in women whose low desire has primarily relationship-based, psychological, or hormonal causes rather than central neurobiological ones.

Predictors of better response in trial data include: acquired HSDD (developed after a period of normal function rather than lifelong), generalized distress (present in most situations, not partner-specific), and absence of concurrent untreated depression or antidepressant use. SSRIs and SNRIs suppress melanocortin-related desire pathways, and concurrent use may blunt bremelanotide's effect, though no formal interaction data establishes this conclusively. [4]